CClinicalTrials.gg
Enrolling by invitationNCT06097572ID-in-FAUpdated Mar 28, 2024

Improved Diagnostics in Food Allergy Study

An interventional study of Intranasal food challenge and Mast cell activation test in Food Allergy, sponsored by Imperial College London. Enrolling by invitation at 2 sites in 2 countries. Open to participants aged 2 Years to 18 Years. Per ClinicalTrials.gov, last updated 2024-03-28.

Sponsored by Imperial College London · Not applicable, Interventional, and Diagnostic

From the registry’s dates

  • Primary completion was expected by Jul 2025, 1 year 2 months ago, but the record still lists the study as enrolling by invitation.
Phase
Not applicable
Study type
Interventional
Enrollment
166
Allocation
Non-randomized
Ages
2 Years to 18 Years
Sex
All
01

Study summary

The investigators will conduct low-dose intranasal allergen challenges on children and young people with an indeterminate diagnosis of food allergy to cow's milk or peanut. Blood samples will also be taken, for conventional blood allergy diagnostics (allergy-specific Immunoglobulin E) and mast cell activation test (MAT). The data will be used to determine the diagnostic accuracy of two complementary, novel approaches to diagnose food allergy, in a representative clinical cohort.

02

Conditions studied

03

In context

Hypersensitivity

1,916 studies on the registry are indexed under Hypersensitivity; 265 are open to participants now.

This study's planned enrollment of 166 is above the median of 57 across 1,384 interventional studies indexed under Hypersensitivity.

Browse Hypersensitivity studies →

Lead sponsor

Imperial College London is the lead sponsor of 824 studies on the registry; 178 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 6 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • IgE-sensitisation to peanut, (hen's) egg or cow's milk, with indeterminate clinical (allergy) status, defined as IgE-sensitisation below 95% positive predictive value (PPV) for diagnosis for either allergen-specific IgE or SPT, using published cut-offs OR clinician suspicion of tolerance (on basis of clinical history) despite IgE sensitisation >95% PPV cut-offs.
  • Written informed consent from parent/guardian, with assent from children aged 6 years and above wherever possible. Participants aged over 16 years will need to provide their own informed consent.

Exclusion criteria

Exclusion Criteria:

  • Acute illness or current unstable asthma, defined as:

    1. Febrile ≥38.0oC in last 72 hours
    2. Acute wheeze in last 72 hours requiring treatment
    3. Recent admission to hospital in preceding 2 weeks for acute asthma
  • Current medication

    1. Asthma reliever medication required in preceding 72 hours
    2. Recent administration of a medicine containing antihistamine within the last 3 days
    3. Current oral steroid for asthma exacerbation or course completed within last 2 weeks
  • Unwilling or unable to fulfil study requirements
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
166 participants (estimated)

Study arms

  • Experimental
    Peanut

    Participants with possible allergy to peanut

    Diagnostic Test: Intranasal food challenge · Diagnostic Test: Mast cell activation test

  • Experimental
    Cow's Milk

    Participants with possible allergy to cow's milk

    Diagnostic Test: Intranasal food challenge · Diagnostic Test: Mast cell activation test

Interventions

  • Diagnostic testIntranasal food challenge

    Subjects will undergo an incremental intranasal challenge to initially 0.9% NaCl saline solution, and then increasing doses of the food protein

  • Diagnostic testMast cell activation test

    Blood will be processed for mast cell activation as previously described (https://doi.org/10.1016/j.jaci.2018.01.043)

06

What researchers measure

Primary outcomes

  1. Test performance

    Comparison of test performance characteristics (sensitivity, specificity, measured according to standard statistical methods) for each of the following diagnostic tests, compared to a formal oral food challenge (FC) as the reference standard: i. Intranasal FC (InFC) ii. Skin prick testing iii. Characterisation of serum-specific IgE to whole allergen, components and molecular components iv. Mast cell activation test (MAT) v. Basophil activation test (BAT) (peanut only)

    Time frame: 1 day

Secondary outcomes

  1. Adverse events

    Number of participants who experience a non-allergic adverse event, and/or have symptoms of a systemic allergic reaction) associated with the intranasal food challenge.

    Time frame: 1 day

07

Study locations

2 sites
  • Prof Jonathan Hourihane
    Dublin, Ireland
  • Imperial College Healthcare NHS Trust (St. Mary's Hospital)
    London, United Kingdom
08

References and documents

Individual participant data

Plan to share: Undecided — Anonymised data may be shared upon request to the Chief Investigator.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 28, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06097572
Lead sponsor
Imperial College London
Collaborators
Royal College of Surgeons, Ireland, University of Manchester
Responsible party
Sponsor
First posted
Oct 24, 2023
Start date
Oct 18, 2023
Primary completion
Jul 31, 2025 (estimated)
Completion
Jul 31, 2025 (estimated)
Last update
Mar 28, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion